We are live on ! Find out more
RLMD icon

Relmada Therapeutics

91 hedge funds and large institutions have $40.3M invested in Relmada Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $307K | Put options by funds: $162K

4.49% less ownership

Funds ownership: 63.6% → 59.11% (-4.5%)

17% less funds holding

Funds holding: 110 → 91 (-19)

21% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 33

43% less capital inflows, than outflows

Capital inflows: $6.73M | Capital outflows: $11.8M

70% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 30

Holders
91
Holders Change
-19
Holders Change %
-17.27%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
26
Reduced
33
Closed
30
Calls
$307​K
Puts
$162​K
Net Calls
+$145​K
Net Calls Change
-⁠$5.58​M

RLMD Hedge Fund Activity: Q1 2023 in Review

91 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2023, worth a combined $40.3M — down 40% from $66.8M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of RLMD and 9 opened new positions — a net loss of 21 holders — while 33 trimmed existing stakes and 26 added.

The largest buyer was Palo Alto Investors, opening a new position worth an estimated $1.87M. The largest seller was Millennium Management, cutting an estimated $2.96M.

  • 91 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2023, down from 110 in Q4 2022.
  • Funds reported $40.3M of Relmada Therapeutics stock for Q1 2023, down 40% quarter-over-quarter.
  • 9 funds opened new Relmada Therapeutics positions in Q1 2023 and 30 closed out, a net change of -21 holders.
  • The largest Relmada Therapeutics buyer in Q1 2023 was Palo Alto Investors, an estimated $1.87M added.
  • The largest Relmada Therapeutics seller in Q1 2023 was Millennium Management, an estimated $2.96M sold.

Based on aggregated 13F filings for Q1 2023.